Replies to post #77013 on Biotech Values

[DewDiligence]

Answer to genisi’s VRTX quiz:

I have one for you: What rates were disclosed by Vertex for the first time in this year's EASL?

The SVR rates in PROVE-3 stratified by cirrhosis status:



Blue: “12+12” arm
Green: “24+24” arm
Orange: No-ribavirin arm
Gray: SoC control arm

In the “12+12” arm (green), there was essentially no difference in SVR between cirrhotic and non-cirrhotic patients. Non-cirrhotic patients did somewhat better in the other three arms; however, across all four arms, the difference between cirrhotic and non-cirrhotic patients was not statsig.